StinaMui(Mui)SingelMDPhD

Breast Cancer, Hematologic Oncology

Head of Clinical Development, Oncology, Ascendis Pharma

Dr. Singel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Fax+1 650-498-5840

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2008
University of California (San Diego) Medical CenterResidency, Internal Medicine, 2004 - 2006
University of California San Diego School of MedicineClass of 2004

PubMed

1392 citations
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter von Minckwitz, Chiun Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas
The New England Journal of Medicine. 2019-02-14
63 citations
KIF14 Promotes AKT Phosphorylation and Contributes to Chemoresistance in Triple-Negative Breast Cancer
Stina M. Singel, Crystal Cornelius, Elma Zaganjor, Kimberly Batten, Venetia R. Sarode
Neoplasia. 2014-03-01
27 citations
Ras regulates kinesin 13 family members to control cell migration pathways in transformed human bronchial epithelial cells
Elma Zaganjor, Jihan K. Osborne, Lauren M. Weil, Laura A. Díaz-Martínez, Joshua X. Gonzales
Oncogene. 2014-11-20

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024September 13th, 2024